Hyperphosphatamia in chronic hemodialysis patients is usually treated with aluminium containing phosphate binders. In recent years there has been increasing evidence of serious complications due to aluminium accumulation. We have investigated a new calcium carbonate preparation with an HCl-resistant capsule designed to prevent gastrointestinal side effects. Its phosphate binding capacity in comparison to aluminium chloride hydroxide was investigated in 17 chronic hemodialysis patients. The dose of the phosphate binder was adjusted regularly so that the serum phosphorus levels were below 1.8 mmol/l. The mean dose of aluminium chloride hydroxide was 3.36 g/day and of calcium carbonate 4.96 g/day. The mean (±SD) serum calcium level was 2.58 ± 0.11 mmol/l under aluminium chloride hydroxide and 2.50 ± 0.25 mmol/l under calcium carbonate. The mean phosphorus level was 1.69 ± 0.31 mmol/l under aluminium chloride hydroxide and 1.71 ± 0.33 under cacium carbonate. Serum aluminium fell from 64.5 ± 14.4 μg/l to 28.5 ± 17.5 μg/l after 3 months.
|Translated title of the contribution||Calcium carbonate for treatment of hyperphosphatemia in chronic hemodialysis patients|
|Number of pages||4|
|Journal||Schweizerische Medizinische Wochenschrift|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas